biote (NASDAQ:BTMD – Get Free Report) will likely be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect biote to announce earnings of $0.07 per share and revenue of $46.1240 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.
biote (NASDAQ:BTMD – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). biote had a negative return on equity of 25.72% and a net margin of 8.29%.The firm had revenue of $44.94 million during the quarter, compared to analyst estimates of $46.02 million. On average, analysts expect biote to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
biote Price Performance
BTMD opened at $2.22 on Wednesday. The firm has a market capitalization of $83.58 million, a price-to-earnings ratio of 4.96 and a beta of 1.66. The company’s 50 day simple moving average is $2.19 and its two-hundred day simple moving average is $2.06. biote has a 1-year low of $1.27 and a 1-year high of $4.58.
Analyst Ratings Changes
Get Our Latest Stock Report on BTMD
Institutional Investors Weigh In On biote
Several hedge funds have recently modified their holdings of the stock. Rothschild Wealth LLC purchased a new position in biote during the 4th quarter worth $380,000. WINTON GROUP Ltd purchased a new stake in shares of biote in the third quarter valued at about $309,000. State Street Corp boosted its holdings in shares of biote by 17.3% in the fourth quarter. State Street Corp now owns 600,114 shares of the company’s stock valued at $1,560,000 after acquiring an additional 88,402 shares in the last quarter. Bridgeway Capital Management LLC increased its stake in shares of biote by 142.1% during the second quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company’s stock worth $487,000 after acquiring an additional 71,053 shares during the period. Finally, Man Group plc increased its stake in shares of biote by 419.1% during the second quarter. Man Group plc now owns 64,027 shares of the company’s stock worth $257,000 after acquiring an additional 51,693 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Recommended Stories
- Five stocks we like better than biote
- 3 Unique AI Software Plays With Strong Analyst Support
- Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile
- NVIDIA’s OpenAI Backstop Puts AI Financing Risk in Focus
- UPS Just Gave Investors a Second Chance to Buy
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.
